NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017

View More View Less
  • 1 From Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Memorial Sloan Kettering Cancer Center; University of Wisconsin Carbone Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Mayo Clinic Cancer Center; Moffitt Cancer Center; Fred & Pamela Buffett Cancer Center; Vanderbilt-Ingram Cancer Center; Stanford Cancer Institute; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Roswell Park Cancer Institute; University of Alabama at Birmingham Comprehensive Cancer Center; Fox Chase Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; Huntsman Cancer Institute at the University of Utah; Duke Cancer Institute; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; University of Michigan Comprehensive Cancer Center; University of Colorado Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; UC San Diego Moores Cancer Center; City of Hope Comprehensive Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; Yale Cancer Center/Smilow Cancer Hospital; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; The University of Texas MD Anderson Cancer Center; Massachusetts General Hospital Cancer Center; and National Comprehensive Cancer Network.
Restricted access

The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding locoregional therapy for treatment of patients with hepatocellular carcinoma.

Provided content development and/or authorship assistance.

Supplementary Materials

    • Supplemental Material (PDF 205 KB)
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1952 1196 111
PDF Downloads 576 431 51
EPUB Downloads 0 0 0